scientific program - World Allergy Organization

More documents

Recommendations

Info

MONDAY 64 MONDAY, 8 SEPTEMBER - continued WAO Congress–XVIII ICACI Final Program P-2-25 Clinical effects of salmeterol on patients with bronchial asthma: assessment of respiratory function and QOL Tochigi T1 , Minowa K1 , Egashira Y2 1 2 Kamoike Seikyo Clinic, Kagoshima-shi, Japan, Kyusyu University of Nursing and Social Welfare, Tamana-shi, Japan P-2-26 Short term therapy of budesonide reduces reactivity to inhaled adenosine 5'-monophosphate Gaszczyk G1 , Latos T1 , Bokiej J1 1National Research Institute of Mother and Child, Karpacz, Dolnoslaskie, Poland P-2-27 Secretary of Health of Rio de Janeiro/Brazil: survey on pediatricians’ knowledge of inhalation therapy for asthmatic children Galvao MG1 , Santos MS1 , Ibiapina AI2 , Cunha AC2 1Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil, 2Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil P-2-28 Comparison of traditional Chinese-Japanese herbal medicine bakumondo-to with emedastine difumarate on asthmatic patients with increased cough sensitivity Watanabe NW1 , Gang CG1 , Fukuda TF1 1Dokkyo University School of Medicine, Shimotsuga-gun, Tochigi-ken, Japan P-2-29 Inhibition of airway hyperresponsiveness and inflammation by a nonenzymatic antioxidant-lipoic acid in a mouse model of asthma Cho YS1 , Kim YY1 , Lee HR2 , Lee EY1 , Yoo B1 , Moon HB1 , Lee J1 1Division of Allergy and Rheumatology, Asan Medical Center, Seoul, Republic of Korea, 2Asan Institute for Life Sciences, Seoul, Republic of Korea P-2-30 Comparison of salmeterol inhaler with tulobuterol tape by QOL questionnaire, Asthma Health Questionnaire-34, Japan Komase Y1 , Saitoh H1 , Nakagawa T2 1St. Marianna University, Yokohama-city Hospital, Yokohama, Kanagawa, Japan, 2St. Marianna University, Kawasaki, Kanagawa, Japan P-2-31 New holding chamber improves inhaled dose of HFA salbutamol Donnell D1 13M Pharmaceuticals, Loughborough, Leics, UK P-2-32 A cost comparison of asthma control in children using a staged dose reduction design of fluticasone (F) or beclomethasone extrafine aerosol (Q) Price DA1 1Aberdeen University, Aberdeen, UK P-2-33 Dose-response comparison of beclomethasone extrafine aerosol (Q) from two devices in patients with moderate asthma Gross G1 , Donnell D2 1University of Texas Southwestern Medical School, Dallas, TX, USA, 23M Pharmaceuticals, Loughborough, Leics, UK POSTER SESSIONS P-2-34 A dose reduction comparison of beclomethasone extrafine aerosol (Q) and fluticasone (F) in children with symptomatic asthma Price DA1 , Van Aalderen WMC2 , Price JF3 1 2 Aberdeen University, Aberdeen, UK, Emma’s Children’s Hospital, University of Amsterdam, Amsterdam, Netherlands, 3King’s College Hospital, London, UK P-2-35 Compliance with the treatment in asthmatic school-age children Volonaki HM1 , Volonakis KM1 , Papaioannou DI1 , Volonakis MK1 1Agia Sofia Children’s Hospital, Athens, Greece P-2-36 IL-2 intravenous application as one of the methods of steroid-saving therapy of the patients with severe steroiddependent asthma Tofimov VI1 , Shaporova NL1 , Shiri ZA1 , Ses TP2 1Saint-Petersburg Pavlov’s State Medical University, Saint- Petersburg, Russian Federation, 2Saint-Petersburg Institute of Pulmonology, Saint-Petersburg, Russian Federation P-2-37 Asthma quality of life and systemic safety of beclomethasone extrafine aerosol (Q) and fluticasone (F) in children Van Aalderen WMC1 , Hugen CAC2 , Tiddens HAWM3 1Emma Children’s Hospital, University of Amsterdam, Amsterdam, Netherlands, 2University Lung Centre, Dekkerswald, Netherlands, 3Erasmus Medical Centre/Sophia, Erasmus University, Rotterdam, Netherlands P-2-38 Sparing effect of coenzyme Q10, α-tocopherol and ascorbic acid on the consumption of corticosteroids in allergic asthmatics Gazdik F1 , Gazdikova K1 , Jahnova E1 , Pijak MR1 1Institute of Preventive and Clinical Medicine, Bratislava, Slovak Republic P-2-39 SURF Study: real-life effectiveness of budesonide/ formoterol (B/F) adjustable maintenance dosing Michilis A1 , Peché RVJ2 , Verbraecken JA3 , Vandenhoven G4 , Wollaert L5 , Duquenne V5 1 2 CUB Erasme, Brussels, Belgium, CHU Vesale, Montigny-Le- Tilleul, Belgium, 3University Hospital Antwerp, Antwerp, Belgium, 4SA AstraZeneca NV, Brussels, Belgium, 5Belgium P-2-40 Treatment with Serevent and Flixotide under pressurized aerosols form (MDI) on a lot of children from Galatzi Ierima GA1 1Emergency Hospital for Children, Galatzi, Romania P-2-41 Immediate and long time clinical effect and safety after high-dose of intravenous immunoglobulin therapy in patients with severe asthma Klos K1 , Kruszewski J1 1Department of Infectious Diseases and Allergology, Warsaw, Poland P-2-42 Four-week administration of inhaled budesonide prevents exercise-induced asthma in adolescents with asthma Yagi K 1 , Onda T 2 , Obata T 3 1 Division of Pediatrics, Yagi Clinic, Yokosuka, Kanagawa, Japan, 2 Onda Clinic, Kawasaki, Kanagawa, Japan, 3 Obata Pediatric Clinic, Kawasaki, Kanagawa, Japan
WAO Congress–XVIII ICACI Final Program MONDAY, 8 SEPTEMBER - continued POSTER SESSIONS P-2-43 Epinephrine injection produces adverse effects frequently in asthmatics without β-agonists use Taniguchi M1 , Takeuchi Y1 , Morita S1 , Higashi N1 , Higashi A1 , Akiyama K1 1National Sagamihara Hospital, Sagamihara, Japan P-2-44 Effect of zafirlukast on hyperosmolar nebulized solution induced airway hyperreponsiveness in patients with mild asthma Estruch I1 , Mallorca W1 , Bouly J1 , Ginard A1 , Alfonso L1 , Rodriguez JC1 , Bencomo M1 1Hospital C. Q. “Hnos. Ameijiras,” Ciudad de la Habana, Cuba P-2-45 Effect of a botanical preparation on patients with moderately severe steroid-dependent asthma and allergic rhinitis Luciuk GH1 , Towers GH2 1Richmond Hospital, Richmond, British Columbia, Canada, 2University of British Columbia, Vancouver, British Columbia, Canada Basic Mechanisms P-3-1 This abstract has been rescheduled and can be found on p. 25 P-3-2 The ratio between different fractions of phospholipids in lymphocyte membranes of peripheral blood in atopic children Terechtchenko S1 , Babushkin V2 , Tereshchenko V2 , Karatchenceva N2 1State Medical Research Institute for Northern Problems, Krasnoyarsk, Russian Federation, 2State Krasnoyarsk Medical Academy, Krasnoyarsk, Russian Federation P-3-3 Increased peripheral IL-4 expressing CD4+ (Th2) and IFNgamma expressing CD8+ (Tc1) T cells in patients with Kimura’s Disease Ohta N1 , Fukase S1 , Aoyagi M1 1Yamagata Univ. School of Medicine, Dept. of Otolaryngology, Yamagata, Yamagata, Japan P-3-4 Role of Stat5a in T helper 2 cell differentiation Takatori HT1 , Nakajima HN1 , Hirose KH1 , Kagami SK1 , Saito YS1 , Iwamoto II1 1Chiba University School of Medicine, Chiba, Chiba, Japan P-3-5 The influence of myelopeptides on lymphocyte activation in cultures of PBMC in patients with allergic diseases Titova LD1 , Gudima GO1 , Sidorovitch IG1 1Institute of Immunology, Moscow, Russian Federation P-3-6 Expression of proteins associated with regulated exocytosis in human lymphocytes Odemuyiwa SO1 , Lo K1 , Logan MR1 , Garofoli D1 , Lacy P1 , Moqbel R1 1University of Alberta, Edmonton, Alberta, Canada P-3-7 T cell IL-5 production to Candida albicans secretory aspartic protease 2 is related to non-IgE-mediated late-phase bronchial response Mori A1 , Hashimoto T1 , Taniguchi M1 , Maeda Y1 , Hasegawa M1 , Mita H1 , Akiyama K1 1National Sagamihara Hospital, Clinical Research Center, Sagamihara, Kanagawa, Japan P-3-8 Successful treatment of hypereosinophilic syndrome with azelastine and cepharanthin Ito T1 , Hattori T1 , Ito S2 1Teikyo University School of Medicine, Tokyo, Democratic People’s Republic of Korea, 2Tokatsu Hospital, Chiba, Japan 65 P-3-9 The reason why the serum ECP shows a higher value than the blood plasma ECP Watanabe K1 , Misu T1 , Yamaguchi S1 1Dokkyo University School of Medicine, Koshigaya, Saitama, Japan P-3-10 German cockroach extract enhances effector function, IL-8 production, CD69 expression and activation of p38 MAPK of human eosinophils Sohn MH1 , Kim KE1 , Shin MH1 1Yonsei University College of Medicine, Seoul, Republic of Korea P-3-11 Effect of ozone exposure on the intracellular glutathione redox state in cultured human airway epithelial cells Todokoro MT1 , Mochizuki HM1 , Tokuyama KT1 , Morikawa AM1 , Dobashi KD2 , Mori MM2 1Department of Pediatrics, Gunma University School of Medicine, Maebashi, Gunma, Japan, 2Department of First Internal Medicine, Gunma University School of Medi, Maebashi, Gunma, Japan P-3-12 Humanized RBL-cells as a standardized in vitro test for the determination of the allergenic potency of proteins using human sera Löttkopf D1 , Vogel L1 , Hatahet L1 , Haustein D1 , Vieths S1 1Paul-Ehrlich-Institut, Langen, Germany P-3-13 Possible mechanism involved in the process of mast cell migration in non-allergic condition Kurosawa M1 , Inamura H1 , Okano A1 1Gunma Clinical Research Center for Allergy and Regeneration, Takasaki, Gunma, Japan P-3-14 Isoforms of FcεRIα (RIα) from human basophils are protected against turnover by IgE Jensen BM1 , Hansen SK1 , Skov PS1 , Poulsen LK1 1Allergy Unit FIN 7551, National University Hospital, Copenhagen, Denmark P-3-15 Expression and function of E-cadherin and its hetroligand integrin αE (CD103) β7 on mast cells Tegoshi T1 , Nishida M1 , Arizono N1 1Kyoto Prefectural University of Medicine, Kyoto, Japan P-3-16 The action mechanism of dexamethasone for the inhibition of the antigen-induced interleukin-13 production in RBL- 2H3 cells Hirasawa N1 , Izumi I1 , Ohuchi K1 1Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan P-3-17 The adjuvant effects of alum are exerted through activation of a wide variety of cells: implication for allergic diseases Haile S1 , HayGlass KT1 1Dept. of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada P-3-18 Alternative maturation of mast cells acquiring the responsiveness to substance P Okabe T1 , Hide M1 , Hiragun T1 , Morita E1 , Yamamoto S1 1Department of Dermatology, Hiroshima Univ. Graduate School of Medicine, Hiroshima, Japan P-3-19 Olopatadine hydrochloride differentially modulates IL-4 expression and degranulation by FcεRI signal transduction in RBL-2H3 cells Hasegawa K 1 , Matsubara M 1 , Ohmori K 1 1 Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., Sunto-gun, Shizuoka, Japan MONDAY
Page 1:
FINAL PROGRAM World Allergy Organiz
Page 4 and 5:
2 WAO Congress-XVIII ICACI Final Pr
Page 6 and 7:
4 World Allergy Organization (WAO)-
Page 8 and 9:
6 WAO Congress-XVIII ICACI Final Pr
Page 10 and 11:
8 sneezing runny nose itchy nose it
Page 12 and 13:
10 PRECAUTIONS (continued) ADVERSE
Page 14 and 15:
12 WAO Congress-XVIII ICACI Final P
Page 16 and 17: 14 WAO Congress-XVIII ICACI Final P
Page 23 and 24: WAO Congress-XVIII ICACI Final Prog
Page 25 and 26: Whistler alpine resort WAO Congress
Page 29 and 30: XXIII EAACI Congress 12-16 June 200
Page 31 and 32: 7:00 8:00 9:00 10:00 11:00 12:00 13
Page 49 and 50: WEDNESDAY WEDNESDAY SEPTEMBER SEPTE
Page 51 and 52: www.annualmeeting.aaaai.org Visit w
Page 59 and 60: Presenting authors indicated in bol
Page 61 and 62: FRIDAY, 12 SEPTEMBER WAO Congress-X
Page 63 and 64: Imagine research targeting IgE, a k
Page 65: WAO Congress-XVIII ICACI Final Prog
Page 98 and 99: 96 PLAN TO ATTEND! SOYEZ DES NÔTRE
Page 100 and 101: 98 Dolovich, Myrna Canada BR86 Dubo
Page 102 and 103: 100 Schnuch, Axel Germany BR88 Scho
Page 104 and 105: 102 201 ACII - Journal of the World
Page 106 and 107: 104 WAO Congress-XVIII ICACI Final
Page 116 and 117:
114 Crowne Plaza Hotel Georgia 801
Page 118 and 119:
116 WAO Congress-XVIII ICACI Final
Page 120 and 121:
118 (salmeterol xinafoate/fluticaso
Page 122 and 123:
COPD, the most commonly reported dr
Page 124 and 125:
122 WAO Congress-XVIII ICACI Final
Page 126 and 127:
124 Seaplane landing at sunset Gran
Page 128:
DS2 - Dinner Symposium Monday, 8 Se
show all

scientific program - World Allergy Organization

Create successful ePaper yourself

Delete template?

Save as template?